The Touchstone Growth Opportunities Fund (Class A) outperformed its benchmark Index, for Q4 of 2024. Click here to read the ...

"The sum cost to taxpayers is probably over a billion dollars...and if that's government efficiency, then I'm the man in the ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $201.33, a high estimate of $250.00, and a low estimate of $130.00. This current average has ...

HC Wainwright & Co. analyst Mitchell Kapoor downgraded Sarepta Therapeutics, Inc. SRPT from Neutral to Sell and lowered the ...

Indeed, the backdrop is set fair. Around 62% of group revenue is derived from UK defence, where the latest government announcement has pledged to spend 5% of GDP by 2035, leaving the door ajar for ...